Choose from weight loss pills or self-injections, all UK-licensed and designed to fit your lifestyle together with healthy eating.






*STEP UP, 72-week study of adults with obesity using Wegovy (semaglutide 7.2mg). Individual results vary.
**SELECT study; Wegovy shown to cut the risk of major cardiovascular events by 20% in adults with obesity and heart disease. Individual results vary.
†SURMOUNT-1, 72-week study of adults with obesity using Mounjaro (tirzepatide 15mg). Individual results vary.

Our medical team are based in the UK and registered with the General Medical Council and General Pharmaceutical Council.
Injectable GLP-1 treatments like Wegovy and Mounjaro help regulate appetite and improve feelings of fullness, supporting steady, sustainable weight loss when used alongside healthy lifestyle changes.
Mounjaro® stands out as the most effective dual acting GIP + GLP-1.
In 72 weeks, people taking Mounjaro 15mg in a clinical study lost an average of 22.5% of their body weight when taken as directed. This means that someone who weighs 100kg may lose 22.5kg on average in 72 weeks (1 year, 5 months).*
What about Wegovy? In 72 weeks, people taking Wegovy 7.2mg in a clinical study lost an average of 20.7% of their body weight when taken as directed. This means that someone who weighs 100kg may lose 20.7kg on average in 72 weeks (1 year, 5 months).**
These are examples only. It is not a prediction of individual results.
*SURMOUNT-1, 72-week study of adults with obesity using Mounjaro (tirzepatide 15mg). Individual results vary.
**STEP UP, 72-week study of adults with obesity using Wegovy (semaglutide 7.2mg). Individual results vary.
It’s 100% online and takes only 2 minutes to see your recommended options.
Check your eligibility to see treatments and pricingFill out a quick consultation to check your eligibility and see prices